Lillie Named Acting Director for FDA's Office of Drug Safety

Ralph Lillie has officially taken over as acting director of the FDA's Office of Drug Safety (ODS), the agency announced.

Lillie replaces Paul Seligman, who is returning to his position as director for the FDA's Office of Pharmacoepidemiology and Statistical Science. The FDA said Lillie will remain in place as acting ODS director until the agency finishes its ongoing national search for a permanent director.

Lillie previously served as deputy director of the FDA's Office of Postmarketing Drug Risk Assessment, the office that preceded ODS, from 1997 through late 1999. He then served as director of the Office of Information Technology until late 2001. Lillie most recently worked in Center for Drug Evaluation and Research's Office of Executive Operations, where he has led the center's emergency preparedness efforts.